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expenditure estimation. Information of physician visits, hospital admission rate, 
medical expenditure and its constitutions, length of stay were analyzed using 
STATA 11. RESULTS: A total of 612,227 insured urban employees were diabetes, 
accounting for 5.2% of population in the program of UEBMI in Beijing during 
2010.10.01 to 2011.09.30. Annual outpatient visits were37.4 times/person and the 
cost was CNY (Chinese Yuan) 388.42/visit, resulting in CNY 14526.91 for annual 
outpatient expenditure. The annual hospital admission rate of the investigated 
people with diabetes was 7.08%. For those who had used inpatient services, 
annual hospital admissions were 1.78 times/person (length of stay was 16.35 
days) and the cost was CNY 15070.99/admission, resulting in CNY 26826.37 for 
annual inpatient expenditure. The total of annual medical expenditure was 
CNY16426.21/person, of which, the cost of western drugs, Chinese traditional 
drugs, treatment, laboratory test, examination and others accounted for 48.46%, 
30.76%, 9.08%, 5.17%, 4.65% and 1.88% respectively. The cost of insulin accounts 
for 2.80% of total medical expenditure. CONCLUSIONS: The proportion of people 
with diabetes in the UEBMI program in Beijing is consistent with the high 
diabetes prevalence reported from other epidemiological studies. Diabetes is 
becoming a chronic epidemic disease with major public concern. This study 
showed that in Beijing, significant amount of societal and medical resources 
were consumed by people with diabetes. Early glycemic control and appropriate 
drug utilization should be the key to reduce the burden of diabetes.  
 
PDB36  
ANNUAL HEALTH CARE UTILIZATION AND COSTS IN CUSHING'S DISEASE 
PATIENTS IN THE UNITED STATES  
Broder M1, Neary MP2, Chang E1, Ludlam W2, Cherepanov D1 
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA  
OBJECTIVES: Cushing’s disease (CD) is a rare disorder resulting from 
adrenocorticotropic hormone secreting pituitary tumor; limited US data are 
available on health care utilization for this rare condition. We evaluated health 
care utilization and costs associated with CD. METHODS: We identified CD 
patients in 2010 in claims databases (Thomson Reuters MarketScan Commercial; 
IMS Health PharMetrics). Since no CD diagnosis code exists, patients were 
identified with a claim for Cushing’s syndrome and either benign pituitary 
adenomas or hypophysectomy (adenectomy) and continuous-enrollment in the 
study year. We estimated total and CD-related utilization and costs using 
pharmacy and medical claims. CD-related outcomes were determined using 
claims with primary diagnosis of Cushing’s syndrome, benign pituitary 
adenoma, or claims with CD treatment (pharmacologic/surgery/radiotherapy). 
RESULTS: We identified 685 CD patients across US (mean age: 41.7years; 81% 
female; mean Charlson-comorbidity: 1.6; mean no. chronic conditions: 4.2); 30.5% 
(209) patients had diabetes, 22.5% had psychiatric disturbances, 8.6% had 
osteoporosis, 8% had cardiovascular disease/stroke, 5.5% had kidney stones, and 
0.7% had compression fracture of vertebra. 38.4% patients had inpatient 
hospitalizations and 34.2% had emergency department visits. Patients had a 
mean of 19.8 physician office visits. CD-related hospitalization was observed in 
26.9%, emergency department visits in 0.9%, CD-treatment in 36.8%. Patients had 
mean of 3.2 CD-related visits. Mean overall costs were $34,992 (SD:$45,811; 
median:$18,031): $3,597 (SD:$6,323) were pharmacy and $31,395 (SD:$44,082) were 
medical costs. Of this total, CD-related costs accounted for $14,310 (SD:$25,161; 
median:$2,079): $9,353 (SD:$19,259) from treatment and $4,957 (SD:$11,805) from 
non-treatment costs. CONCLUSIONS: Economic burden of CD is substantial, with 
hospitalizations or emergency department visits observed in >34% patients, 19.8 
office visits/patient, and up to $35,000 in annual total cost. Direct CD-related 
costs are likely underestimated because of under-coding of CD in claims and use 
of primary diagnosis claims only. Future research should further examine CD-
comorbidity costs and impact of long-term comorbidities of CD.  
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OBJECTIVES: To assess a) the economic impact of diabetes on quality of life, 
disabilities and health utilities, the income, employment and education of patients 
and their families in Argentina, and b) compare these costs with those recorded in 
people without diabetes. METHODS: Case-control study comparing cases with 
T2DM with or without chronic complications and controls without diabetes (paired 
by age and gender) and social contexts. Data was obtained by telephone interviews 
(March-April 2011) using identical questionnaire. Interview data were 
supplemented with data obtained from clinical records to fully describe the 
subjects’ resources utilization and costs of care. Statistical analysis was done using 
ANOVA or Kruskal-Wallis and Chi-square (in proportions) tests and the SPSS 
version 15. The study had ethical clearance and all subjects provided oral informed 
consent. RESULTS: We interviewed 774 non diabetic controls, 387 people with 
T2DM without complications, and 387 people with T2DM and complications); 
mostly female (54.8% in each group). The diabetes duration in the group with 
complications was significantly higher than in the group without complications 
(8.1±8.4 vs. 10.8±9.0). Persons with T2DM with complications have significantly 
lower salaries, higher monthly expenditures (with lower expenditure/income ratio), 
lower percentage of people with university degree, higher hospitalization rate and 
resources consumption; they also have lost more working days (16.2) than those 
either with T2DM without complications (8.48) or those without T2DM (7.78). People 
with T2DM with complications have significantly higher direct medical and indirect 
cost. CONCLUSIONS: This report shows objectively the heavy burden of diabetes 
and its complications for the patient, its family, the health systems and the overall 
society in Argentina. The data provide a serious warning to health care authorities 
to strengthen the implementation of prevention strategies to reduce this burden.  
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OBJECTIVES: Type-2 diabetes mellitus (T2DM), the most common form of 
diabetes (>90% of all cases), is typically associated with adult obesity. Recently, 
increasing attention been given to the growing prevalence of disease among 
pediatric populations. This study assessed trends in pediatric T2DM 
hospitalization and aspects of related care in the US. METHODS: Data for 
pediatric (≤20 years) hospitalizations with a primary diagnosis of T2DM (ICD-9-
CM codes 250.x0 and 250.x2) from the 2000, 2003, 2006, and 2009 HCUP Kids’ 
Inpatient Databases were analyzed. Weighted estimates of the number of T2DM-
related hospitalizations and associated resource-based outcomes (i.e., total 
charges, length of stay [LOS]) were derived. RESULTS: Between 2000 and 2009, 
rates of pediatric T2DM-related hospitalizations (per 100,000 2010 US pediatric 
population) increased from 2.0/100,000 in 2000 to 2.7/100,000 in 2003 and 
3.5/100,000 in 2006, before falling modestly to 2.7/100,000 in 2009. Mean LOS for 
these hospitalizations remained fairly consistent over time (3.2 days in 2000, 3.3 
days in 2003, 3.1 days in 2006, and 2.9 days in 2009). Mean charges (2012 USD) for 
T2DM-related stays have increased nearly 34%, from $13,775 (2000) to $18,432 
(2009). Finally, total pediatric T2DM-related inpatient charges increased by more 
than 147% percent between 2000 and 2006, from $21.5M (2012 USD) to $53.3M, 
before falling slightly in 2009 to $42.4M. CONCLUSIONS: We observed increases 
in rates of pediatric T2DM-related hospitalization over time, with substantial 
growth in the economic burden associated with these stays (i.e., nearly a 150% 
increase in total charges between 2000 and 2006). The increasing hospitalization 
rates are consistent with growing prevalence of obesity among pediatrics in the 
US. These findings should further emphasize the need for interventions targeted 
at mitigating and managing factors associated with the risk of T2DM (e.g., 
obesity) among children.  
 
PDB39  
SYSTEMATIC LITERATURE REVIEW OF COSTS RELATED TO PATIENTS WITH 
TYPE-2 DIABETES MELLITUS EXPERIENCING A STROKE OR MYOCARDIAL 
INFARCTION  
Brennan VK1, Colosia AD2, Copley-Merriman C3, Hass B4, Palencia R5 
1RTI Health Solutions, Sheffield, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA, 
3RTI Health Solutions, Ann Arbor, MI, USA, 4Boehringer Ingelheim GmbH, Ingelheim, Germany, 
5Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany  
OBJECTIVES: Patients with type 2 diabetes mellitus (T2DM) are at greater risk of 
experiencing a stroke or myocardial infarction (MI) than those without T2DM. A 
systematic literature review summarized published cost estimates of stroke and 
MI to better understand the economic burden for T2DM patients experiencing 
these comorbidities. METHODS: Electronic databases (2001-2011) and conference 
abstracts (2011-2012) were searched for publications on costs, utilities, and 
quality of life in the English language. This review reports the cost estimates 
identified. Costs were converted to year 2011 pounds sterling using purchasing 
power parity data and inflation indices. RESULTS: Fifty-one studies (11 primary 
cost studies; 40 economic evaluations) were identified presenting costs 
associated with an MI and/or stroke in patients with T2DM. All studies were 
performed in adults. No studies accounted for event severity. Nine primary cost 
studies reported per-patient direct costs for the year of a nonfatal event. Cost 
estimates ranged from £5,034 to £29,034 for MI and from £1,721 to £38,448 for 
stroke. For subsequent years, cost studies reported either annual or total follow-
up costs. Annual costs for stroke ranged from £639 to £12,831; for MI, 1 study 
reported a cost of £1,605. Total follow-up costs ranged from £284 to £8,988 for 
stroke and from £284 to £1,123 for MI. Only 1 study estimated direct costs for 
fatal events: £2,463 for MI and £6,645 for stroke. None of the 11 primary cost 
studies reported indirect costs associated with MI or stroke. However, 1 of the 40 
economic evaluations identified reported indirect costs for the event year and 
subsequent years. CONCLUSIONS: Literature on costs for MI and stroke specific 
to T2DM patients is sparse, with extensive variability between estimates 
identified. Further studies are needed to provide reliable cost estimates by 
severity of stroke and MI events in T2DM patients of all ages.  
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OBJECTIVES: To evaluate the short-term cost-effectiveness of Liraglutide versus 
Insulin Glargine in patients with type 2 diabetes (T2DM) using a composite 
endpoint from clinical trials and the incremental medical cost in a Chinese 
setting. METHODS: The cost-effectiveness analysis was calculated as the 
incremental cost per successfully treated patient of Liraglutide versus Insulin 
Glargine at week 26. Three cohorts of 100 patients each with Liraglutide 1.2mg, 
Liraglutide 1.8mg and Insulin Glargine were established for comparison. 
Effectiveness data of patients with T2DM achieving the composite endpoint of 
HbA1c<7.0%, no weight gain, and no hypoglycaemia at week 26 from a meta-
analysis. Safety data including hypoglycaemia and serious adverse events were 
derived from ‘Liraglutide Effect and Action in Diabetes’ trials. Medical costs 
